 Leukemia, Myeloid, Acute
"Leukemia, Myeloid, Acute" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Descriptor ID |
D015470
|
| MeSH Number(s) |
C04.557.337.539.550
|
| Concept/Terms |
Leukemia, Myeloid, Acute- Leukemia, Myeloid, Acute
- ANLL
- Leukemia, Myeloblastic, Acute
- Leukemia, Myelocytic, Acute
- Leukemia, Myelogenous, Acute
- Nonlymphocytic Leukemia, Acute
- Acute Nonlymphocytic Leukemia
- Acute Nonlymphocytic Leukemias
- Leukemia, Acute Nonlymphocytic
- Leukemias, Acute Nonlymphocytic
- Nonlymphocytic Leukemias, Acute
- Leukemia, Nonlymphocytic, Acute
- Myeloblastic Leukemia, Acute
- Acute Myeloblastic Leukemia
- Acute Myeloblastic Leukemias
- Leukemia, Acute Myeloblastic
- Leukemias, Acute Myeloblastic
- Myeloblastic Leukemias, Acute
- Myelocytic Leukemia, Acute
- Acute Myelocytic Leukemia
- Acute Myelocytic Leukemias
- Leukemia, Acute Myelocytic
- Leukemias, Acute Myelocytic
- Myelocytic Leukemias, Acute
- Myelogenous Leukemia, Acute
- Acute Myelogenous Leukemia
- Acute Myelogenous Leukemias
- Leukemia, Acute Myelogenous
- Leukemias, Acute Myelogenous
- Myelogenous Leukemias, Acute
- Myeloid Leukemia, Acute
- Nonlymphoblastic Leukemia, Acute
- Acute Nonlymphoblastic Leukemia
- Acute Nonlymphoblastic Leukemias
- Leukemia, Acute Nonlymphoblastic
- Leukemias, Acute Nonlymphoblastic
- Nonlymphoblastic Leukemias, Acute
- Acute Myeloid Leukemia
- Acute Myeloid Leukemias
- Leukemia, Acute Myeloid
- Leukemias, Acute Myeloid
- Myeloid Leukemias, Acute
- Leukemia, Nonlymphoblastic, Acute
|
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myeloid, Acute".
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myeloid, Acute".
- Leukemia, Myeloid, Acute
- Leukemia, Basophilic, Acute
- Leukemia, Eosinophilic, Acute
- Leukemia, Erythroblastic, Acute
- Leukemia, Mast-Cell
- Leukemia, Megakaryoblastic, Acute
- Leukemia, Monocytic, Acute
- Leukemia, Promyelocytic, Acute
This graph shows the total number of publications written about "Leukemia, Myeloid, Acute" by people in this website by year, and whether "Leukemia, Myeloid, Acute" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 3 | 1 | 4 | | 1981 | 1 | 3 | 4 | | 1982 | 0 | 2 | 2 | | 1983 | 2 | 0 | 2 | | 1984 | 2 | 0 | 2 | | 1986 | 2 | 0 | 2 | | 1987 | 1 | 0 | 1 | | 1988 | 4 | 0 | 4 | | 1989 | 6 | 0 | 6 | | 1990 | 2 | 0 | 2 | | 1991 | 4 | 1 | 5 | | 1992 | 4 | 0 | 4 | | 1993 | 9 | 1 | 10 | | 1994 | 4 | 1 | 5 | | 1995 | 3 | 2 | 5 | | 1996 | 2 | 2 | 4 | | 1997 | 2 | 2 | 4 | | 1998 | 3 | 1 | 4 | | 1999 | 2 | 1 | 3 | | 2000 | 6 | 1 | 7 | | 2001 | 4 | 0 | 4 | | 2002 | 7 | 2 | 9 | | 2003 | 7 | 0 | 7 | | 2004 | 4 | 1 | 5 | | 2005 | 6 | 0 | 6 | | 2006 | 7 | 1 | 8 | | 2007 | 8 | 1 | 9 | | 2008 | 17 | 0 | 17 | | 2009 | 17 | 0 | 17 | | 2010 | 16 | 1 | 17 | | 2011 | 15 | 2 | 17 | | 2012 | 23 | 1 | 24 | | 2013 | 23 | 1 | 24 | | 2014 | 23 | 0 | 23 | | 2015 | 28 | 0 | 28 | | 2016 | 21 | 3 | 24 | | 2017 | 15 | 5 | 20 | | 2018 | 19 | 2 | 21 | | 2019 | 18 | 1 | 19 | | 2020 | 9 | 2 | 11 |
To return to the timeline, click here.
Below are the most recent publications written about "Leukemia, Myeloid, Acute" by people in Profiles.
-
Pollyea DA, Pratz K, Letai A, Jonas BA, Wei AH, Pullarkat V, Konopleva M, Thirman MJ, Arellano M, Becker PS, Chyla B, Hong WJ, Jiang Q, Potluri J, DiNardo CD. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. Am J Hematol. 2021 02 01; 96(2):208-217.
-
Arber DA, Erba HP. Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC). Am J Clin Pathol. 2020 11 04; 154(6):731-741.
-
Burd A, Levine RL, Ruppert AS, Mims AS, Borate U, Stein EM, Patel P, Baer MR, Stock W, Deininger M, Blum W, Schiller G, Olin R, Litzow M, Foran J, Lin TL, Ball B, Boyiadzis M, Traer E, Odenike O, Arellano M, Walker A, Duong VH, Kovacsovics T, Collins R, Shoben AB, Heerema NA, Foster MC, Vergilio JA, Brennan T, Vietz C, Severson E, Miller M, Rosenberg L, Marcus S, Yocum A, Chen T, Stefanos M, Druker B, Byrd JC. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020 12; 26(12):1852-1858.
-
DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, Konopleva M, Döhner H, Letai A, Fenaux P, Koller E, Havelange V, Leber B, Esteve J, Wang J, Pejsa V, Hájek R, Porkka K, Illés Á, Lavie D, Lemoli RM, Yamamoto K, Yoon SS, Jang JH, Yeh SP, Turgut M, Hong WJ, Zhou Y, Potluri J, Pratz KW. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020 08 13; 383(7):617-629.
-
Garcia-Manero G, Griffiths EA, Steensma DP, Roboz GJ, Wells R, McCloskey J, Odenike O, DeZern AE, Yee K, Busque L, O'Connell C, Michaelis LC, Brandwein J, Kantarjian H, Oganesian A, Azab M, Savona MR. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020 08 06; 136(6):674-683.
-
Saevarsdottir S, Olafsdottir TA, Ivarsdottir EV, Halldorsson GH, Gunnarsdottir K, Sigurdsson A, Johannesson A, Sigurdsson JK, Juliusdottir T, Lund SH, Arnthorsson AO, Styrmisdottir EL, Gudmundsson J, Grondal GM, Steinsson K, Alfredsson L, Askling J, Benediktsson R, Bjarnason R, Geirsson AJ, Gudbjornsson B, Gudjonsson H, Hjaltason H, Hreidarsson AB, Klareskog L, Kockum I, Kristjansdottir H, Love TJ, Ludviksson BR, Olsson T, Onundarson PT, Orvar KB, Padyukov L, Sigurgeirsson B, Tragante V, Bjarnadottir K, Rafnar T, Masson G, Sulem P, Gudbjartsson DF, Melsted P, Thorleifsson G, Norddahl GL, Thorsteinsdottir U, Jonsdottir I, Stefansson K. FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease. Nature. 2020 08; 584(7822):619-623.
-
Goldberg AD, Atallah E, Rizzieri D, Walter RB, Chung KY, Spira A, Stock W, Tallman MS, Cruz HG, Boni J, Havenith KEG, Chao G, Feingold JM, Wuerthner J, Solh M. Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. Leuk Res. 2020 08; 95:106385.
-
Hsu J, Van Besien K, Baron F. Busulfan or melphalan: is there a better conditioning regimen for allogeneneic transplantation? Leuk Lymphoma. 2020 07; 61(7):1529-1534.
-
Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, Sweiss K, Griffin S, Cahill K, Konig H, Esen A, Shergill A, Odenike O, Stock W, Quigley JG. A multi-institutional comparison of mitoxantrone, etoposide, and cytarabine vs high-dose cytarabine and mitoxantrone therapy for patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. 2020 08; 95(8):937-943.
-
Rogers HJ, Wang X, Xie Y, Davis AR, Thakral B, Wang SA, Borthakur G, Cantu MD, Margolskee EM, Philip JKS, Sukhanova M, Bagg A, Bueso-Ramos CE, Orazi A, Arber DA, Hsi ED, Hasserjian RP. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study. Am J Hematol. 2020 07; 95(7):799-808.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|